The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
Open accessAbstract
Purpose Ipilimumab (Ipi), a monoclonal antibody against cytotoxic T-lymphocyte antigen-4, has been shown to improve survival in patients with metastatic melanoma. In this single-institution study, we investigate the safety and efficacy of stereotactic radiosurgery (SRS) for patients with melanoma brain metastases (BMs) who also received Ipi. Methods From 2005 to 2011, 46 patients with melanoma received Ipi and underwent single fraction SRS for BMs. A total of 113 BMs (91% intact, 9% post-operative) were treated with median dose 21Gy (15-24Gy). Ipi was given at 3mg/kg (54%) or 10mg/kg (46%) for a median of 4 doses (1-21). Adverse events were recorded using CTCAE 3.0. Kaplan-Meier methods were used to estimate survival and Cox regression was used to investigate associations. Results Fifteen patients received SRS during Ipi, 19 received SRS before Ipi, and 12 received SRS after Ipi. Overall survival (OS) was significantly associated with timing of SRS/Ipi (p=0.035) and melanoma-specific graded prognostic assessment (p=0.013). Patients treated with SRS during or before Ipi had better OS and less regional recurrence (RR) than those treated with SRS after Ipi (1-yr OS 65% vs. 56% vs. 40%, p=0.008; 1-yr RR 69% vs. 64% vs. 92%, p=0.003). SRS during Ipi also yielded a trend toward less local recurrence (LR) than SRS before or after Ipi (1-yr LR 0% vs. 13% vs. 11%, p=0.21). On MRI, an increase in BM diameter to >150% was seen in 50% of patients treated during or before Ipi but only 13% of patients treated after Ipi. Grade 3-4 toxicities were seen in 20% of patients. Conclusion Overall, the combination of Ipi and SRS appears to be well tolerated. Concurrent delivery of Ipi and SRS is associated with favorable locoregional control and possibly longer survival. It may also cause a temporary increase in tumor size, possibly due to enhanced immunomodulatory effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Self-citationImmunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Self-citationDewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Self-citationRadiation therapy oncology group: Radiosurgery quality assurance guidelines
Shaw, E., Kline, R., Gillin, M., Souhami, L., Hirschfeld, A., Dinapoli, R., & Martin, L. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90548-a · Cited by 748
Golden, E. B., Demaria, S., Schiff, P. B., Chachoua, A., & Formenti, S. C. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0115 · Cited by 688
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
Sampson, J. H., Carter, J. H., Friedman, A. H., & Seigler, H. F. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.88.1.0011 · Cited by 560
Prognostic factors for survival in melanoma patients with brain metastases
Davies, M. A., Liu, P., McIntyre, S., Kim, K. B., Papadopoulos, N., Hwu, W., Hwu, P., & Bedikian, A. (2011) · Cancer · doi:10.1002/cncr.25634 · Cited by 548
Improved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R., Anderson, A., Humphrey, R., Blumenstein, B., Old, L., & Wolchok, J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 518
Self-citationDeterminants of Outcome in Melanoma Patients With Cerebral Metastases
Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K., Zacest, A. C., Besser, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.140 · Cited by 445
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.017 · Cited by 387
Self-citationRadiation as an immunological adjuvant: current evidence on dose and fractionation
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 332
Knisely, J. P. S., Yu, J. B., Flanigan, J., Sznol, M., Kluger, H. M., & Chiang, V. L. S. (2012) · Journal of Neurosurgery · doi:10.3171/2012.5.jns111929 · Cited by 330
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
Mathew, M., Tam, M., Ott, P. A., Pavlick, A. C., Rush, S. C., Donahue, B. R., Golfinos, J. G., Parker, E. C., Huang, P. P., & Narayana, A. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835f3d90 · Cited by 178
Hodi, F. S., Oble, D. A., Drappatz, J., Velazquez, E. F., Ramaiya, N., Ramakrishna, N., Day, A. L., Kruse, A., Rae, S. M., Hoos, A., et al. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1183 · Cited by 167
Outcome predictors of Gamma Knife surgery for melanoma brain metastases
Liew, D. N., Kano, H., Kondziolka, D. S., Mathieu, D., Niranjan, A., Flíckinger, J. C., Kirkwood, J. M., Tarhini, A. A., Moschos, S. J., & Lunsford, L. D. (2010) · Journal of neurosurgery · doi:10.3171/2010.5.jns1014 · Cited by 156
Abscopal Effect in a Patient with Melanoma
Hiniker, S. M., Chen, D. S., & Knox, S. J. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1203984 · Cited by 143
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases
Weber, J. S., Amin, A., Minor, D. R., Siegel, J., Berman, D., & O'Day, S. J. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834d3d88 · Cited by 113
Tazi, K., Hathaway, A. R., Chiuzan, C. C., & Shirai, K. (2014) · Cancer Medicine · doi:10.1002/cam4.315 · Cited by 111
Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade
Pilones, K. A., Kawashima, N., Yang, A. M., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1277 · Cited by 102
Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS)
Samlowski, W. E., Watson, G. A., Wang, M., Rao, G., Klimo, P., Boucher, K. M., Shrieve, D. C., & Jensen, R. L. (2007) · Cancer · doi:10.1002/cncr.22605 · Cited by 101
Stereotactic radiosurgery for brain oligometastases: good for some, better for all?
Gupta, T. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi392 · Cited by 20
Cited by
Sharabi, A. B., Lim, M., DeWeese, T. L., & Drake, C. G. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00007-8 · Cited by 899
Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., Marosi, C., Metellus, P., Radbruch, A., Villa Freixa, S. S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now241 · Cited by 496
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
Chen, L., Douglass, J., Kleinberg, L., Ye, X., Marciscano, A. E., Forde, P. M., Brahmer, J., Lipson, E., Sharfman, W., Hammers, H., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.11.041 · Cited by 329
Tang, C., Welsh, J. W., de Groot, P., Massarelli, E., Chang, J. Y., Hess, K. R., Basu, S., Curran, M. A., Cabanillas, M. E., Subbiah, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1432 · Cited by 321
Metadata
- Authors
- Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2015-06
- Volume
- 92
- Issue
- 2
- Pages
- 368-375
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2074933858
- Cited by
- 390
- References
- 27
- FWCI
- 40.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.